Syndax Q4 2025 slides: dual product launch drives revenue beat

Syndax beat Q4 2025 revenue expectations with $68.7M (8.82% above a $63.13M consensus) driven by Revuforj ($44.2M, +38% QoQ) and Niktimvo ($56.0M, collaboration revenue $19.4M in Q4). EPS missed at -$0.78 vs. -$0.59 expected, but shares jumped ~4.6% after hours to $21.71 and extended to $24.29 as investors rewarded strong commercial uptake and 628% YoY revenue growth (2025 revenue $172.4M vs $23.7M in 2024). The company ended 2025 with $394.1M cash, guided combined R&D and SG&A of ~ $400M in 2026 (ex. $50M stock option expense), and expects to reach profitability without additional capital raises, though a -54% gross margin and ongoing heavy R&D ($258.8M) underline near-term profitability risk.

Analysis

Syndax's commercial momentum has meaningfully derisked the story but introduced a timeline mismatch: near-term revenues are scaling while the most value-driving pivotal readouts stretch into late-2026/2027. That gap creates a binary path — either continued durable uptake converts into self-funding for multi-year programs, or the company must return to markets at a valuation sensitive to clinical outcomes, amplifying volatility around each trial update.

Second-order effects favor vendors and infrastructure players exposed to rapid launch scale (specialty pharmacies, CDMOs, infusion-center throughput) and create negotiation leverage with payers as durable-use signals emerge. Conversely, competing targeted AML and cGVHD franchises face accelerating head-to-head positioning discussions; payers and guideline committees will re-evaluate line-of-therapy placement if durability persists, which can compress effective duration and pricing for incumbents.

The partnership with a large pharma collaborator reduces single-company execution risk but also concentrates timing risk around milestone recognition and revenue cadence — a lumpier earnings profile that can exaggerate moves on quarterly results. Gross-margin recovery is the critical operational readout between now and clinical catalysts: if margins fail to inflect as volume scales, the market will reprice growth as cash-burning, not self-funding.

Key near-term catalysts to watch are enrollment velocity, real-world persistence metrics from major centers, and the IPF/topline timelines — these will drive step changes in both valuation and payor behavior. Tail risks: safety signals in larger populations, slower-than-guideline adoption, or an unexpected need to raise capital before pivotal data materialize; any of these could erase the current premium rapidly.

Key Decisions for Investors

• Directional, capped-upside: Buy SNDX Jan 2028 30/60 call spread (or equivalent LEAP call spread) sized 2–4% portfolio. Rationale: captures late-2026 IPF readout and 2026 first-line datapoints with defined max loss. Risk/Reward: limited downside (premium paid) vs ~3x+ upside if readouts are positive and margins recover.
• Hedged equity: Initiate a 3–5% long equity position in SNDX and buy 9–12 month protective puts (e.g., 2027 Jan puts ~10–15% OTM). Rationale: participate in commercial re-rate while protecting against trial or margin setbacks. Risk/Reward: pay hedge cost to limit >30% downside from adverse clinical/payer events.
• Pair trade to isolate execution: Long SNDX vs short INCY (equal dollar, rebalanced quarterly) for 6–12 months. Rationale: isolates Syndax-specific launch/execution optionality from broader collaborator volatility and hedges market/sector moves. Risk/Reward: profit if Syndax monetizes launches faster than collaboration revenue shifts; risk if collaborator upside outperforms.
• Event-driven protection/short: Buy 6–9 month SNDX puts or short a tactical size ahead of pivotal enrollment or major meeting if enrollment slows or guidance revisions emerge. Rationale: asymmetric downside around missed enrollment/guide cuts. Risk/Reward: high-risk/high-reward — small size advised given binary clinical outcomes.